114 related articles for article (PubMed ID: 10520033)
21. Analysis of the serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and different stages of multiple myeloma.
Scudla V; Petrova P; Minarik J; Pika T; Bacovsky J
Neoplasma; 2011; 58(6):499-506. PubMed ID: 21895403
[TBL] [Abstract][Full Text] [Related]
22. High serum interleukin-2 levels in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.
Cimino G; Avvisati G; Amadori S; Di Gregorio AO; Magliocca V; Petrucci MT; Sgadari C
Nouv Rev Fr Hematol (1978); 1989; 31(5):329-32. PubMed ID: 2587201
[TBL] [Abstract][Full Text] [Related]
23. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group.
Pulkki K; Pelliniemi TT; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
Br J Haematol; 1996 Feb; 92(2):370-4. PubMed ID: 8603002
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
25. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
26. [Biochemical and immunological findings of multiple myeloma].
Asaoku H
Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
[TBL] [Abstract][Full Text] [Related]
27. [The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Bacovský J; Minarík J; Heinzová V; Langová K
Cas Lek Cesk; 2009; 148(7):315-22. PubMed ID: 19642297
[TBL] [Abstract][Full Text] [Related]
28. [The risk of a multiple myeloma in patients with paraproteinemia: a myeloma risk score developed in the region of the Comprehensive Cancer Center West].
Schaar CG; Ong F; Snijder S; Wijermans PW; Franck PF; Kluin-Nelemans JC
Ned Tijdschr Geneeskd; 1998 Jul; 142(28):1591-5. PubMed ID: 9763839
[TBL] [Abstract][Full Text] [Related]
29. A population-based registry on paraproteinaemia in The Netherlands. Comprehensive Cancer Centre West, Leiden, The Netherlands.
Ong F; Hermans J; Noordijk EM; Wijermans PW; Seelen PJ; de Kieviet W; Gerrits WB; Kluin PM; Kluin-Nelemans JC
Br J Haematol; 1997 Dec; 99(4):914-20. PubMed ID: 9432042
[TBL] [Abstract][Full Text] [Related]
30. Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis.
Tienhaara A; Pulkki K; Mattila K; Irjala K; Pelliniemi TT
Br J Haematol; 1994 Feb; 86(2):391-3. PubMed ID: 8199033
[TBL] [Abstract][Full Text] [Related]
31. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
32. [Determination of serum interleukin-6 concentration by an enzyme-linked immunosorbent assay in patients with paraproteinemia].
Yamagishi Y; Hidaka Y; Sasaki K; Nihei K; Itoh Y; Kawai T
Rinsho Byori; 1992 Mar; 40(3):303-10. PubMed ID: 1518181
[TBL] [Abstract][Full Text] [Related]
33. [Values of Detecting the Levels of β2-MG, TNF-α, CRP, IL-6 in the Patients with Multiple Myeloma].
Duan LJ; Li C; Yang RY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1362-5. PubMed ID: 26524038
[TBL] [Abstract][Full Text] [Related]
34. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors.
Turesson I; Abildgaard N; Ahlgren T; Dahl I; Holmberg E; Hjorth M; Nielsen JL; Odén A; Seidel C; Waage A; Westin J; Wislöff F
Br J Haematol; 1999 Sep; 106(4):1005-12. PubMed ID: 10520004
[TBL] [Abstract][Full Text] [Related]
35. Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance.
Bladé J; Filella X; Montoto S; Bosch F; Rosiñol L; Coca F; Giné E; Nadal E; Aymerich M; Rozman M; Montserrat E
Br J Haematol; 2002 May; 117(2):387-9. PubMed ID: 11972522
[TBL] [Abstract][Full Text] [Related]
36. Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma.
Pappa CA; Tsirakis G; Samiotakis P; Tsigaridaki M; Alegakis A; Goulidaki N; Alexandrakis MG
Cancer Invest; 2013 Jul; 31(6):385-9. PubMed ID: 23758184
[TBL] [Abstract][Full Text] [Related]
37. Paraproteinaemia.
Frank LA; Rabin N
Br J Hosp Med (Lond); 2015 Jun; 76(6):C82-5. PubMed ID: 26053916
[No Abstract] [Full Text] [Related]
38. Use of leucocyte alkaline phosphatase (LAP) score in differentiating malignant from benign paraproteinaemias.
Majumdar G; Hunt M; Singh AK
J Clin Pathol; 1991 Jul; 44(7):606-7. PubMed ID: 1713223
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
[TBL] [Abstract][Full Text] [Related]
40. Serum beta-2-microglobulin in the differential diagnosis of monoclonal gammopathies.
Elias J; Dauth J; Senekal JC; van der Walt P; Joubert HF; Kühn F; Greenacre M
S Afr Med J; 1991 Jun; 79(11):650-3. PubMed ID: 2047946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
